Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell ...

Given the success of the previous Research Topic 'Exploring Small Molecule Inhibitors in Cardiovascular and Cerebrovascular Diseases', we are pleased to ...

Pancreatic cancer is one of the deadliest types of cancer, with very few people surviving for more than five years after ...

Blood clots form in response to signals from the lungs of cancer patients -- not from other organ sites, as previously thought -- according to a preclinical study. Clots are the second-leading cause ...

University of Queensland research using natural killer cells may lead to the first new treatment for a devastating childhood ...

The Decipher Bladder Genomic Subtyping Classifier found that patients with luminal tumors may have less aggressive disease.

Van Andel Institute researchers discovered that cancer risk may be determined before birth due to distinct epigenetic states ...

St. David’s Medical Center in Austin is the first hospital in Central Texas to offer histotripsy, a noninvasive ultrasound ...

Scientists have developed an innovative method for growing brain tumors of individual patients in the laboratory that mimic the original structure and the molecular property of the parental tumor as ...

The authors liken the method to the moment just before water reaches 212°F (100°C), when it's neither truly liquid nor truly ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel ...

The heart drug digoxin could potentially be combined with existing cancer therapies to prevent the spread of tumors, an early trial suggests. But questions remain.